

alveolus **DEKA**svitamins.com

Product name	DEKAs Plus chewable tablets			
Pharmaceutical form	chewable tablet			
Quantity	60			
Supplied in	White high-density polyethylene bottle with Child Resistant Closure			
Classification	Food for Special Medical Purposes (FSMP)			
Product Description	DEKAs Plus chewable tablets is a food for special medical purposes intended for the dietary management of patients with cystic fibrosis. DEKAs Plus is a multivitamin and mineral supplement that contains higher amounts of fat- soluble vitamins. DEKAs Plus utilizes a clinically tested delivery technology to enhance absorption of fat-soluble vitamins and nutrients.			
Indications	For the dietary management of patients with cystic fibrosis on the specific recommendation of a Cystic Fibrosis specialist.			
Important notices	Use only under medical supervision. Cannot be used as a sole source of nutrition. Can be used from the age of 4 years. The product poses a health hazard if consumed by persons who do not have the disease (s), disorder(s) or medical conditions for which the product is intended.			
Contraindications:	Use during pregnancy and/or combined use with anticoagulants only after consultation with a doctor.			
Directions for use and storage	Do not use if the seal is broken or missing. Keep out of reach of children. Store at room temperature. Take with meals.			
Recommended dosage	Age 4 to 10 years: 1 chewable tablet daily or as directed by physician. Over age 10: 1-2 chewable tablets per day as directed by a physician.			
Allergens	None			
Nutritional information	See table below			
Ingredients	sugar, dextrose, natural flavors, sodium-L-ascorbate, sweetener (sorbitol), bulking agent (hydroxypropylcellulose), beta-carotene, D-alpha-tocopherol, anti-caking agent (calcium silicate), flavor (citric acid), zinc bisglycinate, nicotinamide, cholecalciferol, phytomenadione, D-alpha-tocopheryl polyethylene glycol-1000 succinate (TPGS), calcium D-pantothenate, anti- caking agent (magnesium stearate), D-biotin, coenzyme Q10, pyridoxine hydrochloride, retinyl palmitate, sodium selenite, thiamin mononitrate, riboflavin, sweetener (sucralose), anti-caking agent (silicon dioxide), cyanocobalamin, antioxidant (tocopherol rich extract), folic acid.			
Distributor	Alveolus Biomedical B.V., Zeist, The Netherlands. info@alveolus.nl			
Manufacturer	Callion Pharma, Jonesborough, USA. www.callionpharma.com			
Shelf life	24 months			
Availability	Alliance Healthcare. www.alliance-healthcare.co.uk			
Universal Product Code (UPC)	868176000152			
Case quantity	24 bottles			
Weight per bottle	227 grams			
ACBS status	Approved and in Part XV of the Drug Tariff (1 May 2018)			
PIP-code	404-1406			
NHS price	£43,34 (VAT on FSMP is o%)			
1				

Alveolus Biomedical B.V.- Platolaan 71 - 3707 GD Zeist (NL) - <u>info@alveolus.nl</u> - T: +31621255794 - Company nr. (KvK) - 62529560 VAT nr.- NL854854083B01 | DEKAsvitamins.com is a registered tradename of Alveolus Biomedical B.V. UK - 2 Sep 2021 - page 1

alveolus **DEKA**svitamins.com

Nutritional information				
contains 60 chewable tablets		1 chewable tablet	100 g	
Energy	kJ / kcal	48 / 12	1577 / 377	
Fat of which	g	0	1,8	
saturates	g	0	1,6	
Carbohydrates of which	g	2,7	88	
Sugars	g	2,1	70	
Protein	g	0	2,5	
Salt	g	0,01	0,42	
Vitamin A as retinyl palmitate	μg RE* (IU)	450 (1500)	14754 (49180)	
Vitamin A as beta-carotene	μg RE* (IU)	5000 (16667)	163937 (546455)	
Vitamin C	mg	70	2295	
Vitamin D3	μg (IU)	50 (2000)	1639 (65574)	
Vitamin E	mg (IU)	67 (100)	2197 (3279)	
Vitamin K1	μg	1000	32787	
Vitamin B1 - Thiamin	mg	1,5	49	
Vitamin B2 - Riboflavin	mg	1,7	56	
Niacin	mg	10	328	
Vitamin B6	mg	1,9	62	
Folic acid	μg	200	6557	
Vitamin B12	μg	12	393	
Biotin	μg	100	3279	
Pantothenic Acid	mg	12	393	
Zinc	mg	10	328	
Selenium	μg	75	2459	
Coenzyme Q10	mg	10	328	

* RE = all trans retinol equivalent

Alveolus Biomedical B.V.- Platolaan 71 - 3707 GD Zeist (NL) - <u>info@alveolus.nl</u> - T: +31621255794 - Company nr. (KvK) - 62529560 VAT nr.- NL854854083B01 | DEKAsvitamins.com is a registered tradename of Alveolus Biomedical B.V. UK - 2 Sep 2021 - page 2